Key facts
- EvlaBio’s last known valuation is $800K (Sep 2022).
- It has raised $24.6M; the latest was Seed Round ($24.4M) in Jul 2025.
- Notable investors include High-Tech Gründerfonds, NRW.Bank, Kurma Partners, Boehringer Ingelheim Venture Fund, AdBio partners — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for EvlaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for EvlaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EvlaBio
Developer of targeted monoclonal antibody-based therapeutics intended for the treatment of left ventricular hypertrophy in chronic kidney disease patients. The company is advancing a monoclonal antibody that blocks harmful signaling in heart muscle cells while preserving beneficial hormone activity, reducing pathological cardiac remodeling and fibrosis, and supporting healthier heart structure and function, enabling chronic kidney disease patients to address severe cardiorenal complications with a more precise, mechanism-driven therapy.
- Sector
- Healthcare
- HQ
- Düsseldorf, Germany
- Founded
- 2022
- Employees
- 7
- Website
- evlabio.com/
- Ownership
- Privately Held (backing)
EvlaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EvlaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EvlaBio in its N-PORT filings yet. We sweep new filings monthly.